Evaluate the pharmacokinetics (PK) of AG 013736 and CP 868,596 when given together with and without docetaxel

Evaluate the PK of CP 868,596 when given in combination with docetaxel

Evaluate the PK of docetaxel when given in combination with CP 868,596, or CP 868,596 plus AG 01373

Enrollment:

0

Study Start Date:

May 2007

Eligibility

Ages Eligible for Study:

18 Years and older (Adult, Senior)

Genders Eligible for Study:

Both

Accepts Healthy Volunteers:

No

Criteria

Inclusion Criteria:

Platinum-pretreated patients with advanced stage IIIb or IV NSCLC

Exclusion Criteria:

Centrally-located tumors

Contacts and Locations

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study.
To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below.
For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00386555